Axsome Therapeutics (AXSM) Raw Materials (2022 - 2026)

Axsome Therapeutics' Raw Materials history runs 5 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• In Q1 2026, Raw Materials rose 2.81% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $11.9 million (up 2.81% YoY), while the FY2025 annual figure was $10.4 million, up 8.76% from the prior year.
• Raw Materials came in at $11.9 million for Q1 2026 at Axsome Therapeutics, up from $10.4 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $12.4 million in Q3 2025 to a low of $2.1 million in Q3 2022.
• A 5-year average of $7.4 million and a median of $7.7 million in 2024 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials jumped 123.78% in 2023 and increased 2.81% in 2026, its largest moves.
• Axsome Therapeutics' Raw Materials stood at $2.5 million in 2022, then jumped by 123.78% to $5.5 million in 2023, then surged by 72.41% to $9.5 million in 2024, then advanced by 8.76% to $10.4 million in 2025, then rose by 14.26% to $11.9 million in 2026.
• According to Business Quant data, Raw Materials over the past three periods registered $11.9 million, $10.4 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison